Connect Biopharma
Market cap $37.3M 64.5M shares (10-Q, Oct 30, 2026) × $0.579 close Nov 17, 2026
Most recent annual filing: 2026-03-31
- Rademikibart atopic dermatitis China decision2H 2026Rademikibart atopic dermatitis China decision, 2H 2026, material
- Rademikibart FDA feedbackDec 2026Rademikibart FDA feedback, Dec 2026, notable
- COPD Phase 3 corporate update1Q 2027COPD Phase 3 corporate update, 1Q 2027, routine
- Nasdaq listing updateMay 11, 2027Nasdaq listing update, May 11, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Discontinued (1)
- rademikibart — Atopic Dermatitis · Connect has decided to not currently pursue further development of rademikibart for AD
Capital (as filed)
- Cash
- $16.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $3.0M Sep 30, 2026
- Operating cash flow
- −$12.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $19.5M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-17 UPDATE: Connect Biopharma (CNTB) - The Going-Concern Flag 🔒 Paid
- 2026-09-30 UPDATE: Connect Biopharma (CNTB) - The Mirror Image ★ Distilled Pro
- 2026-09-16 UPDATE: Connect Biopharma (CNTB) - The Trial Failed. The Drug Might Not Have. 🔒 Paid
- 2026-08-13 UPDATE: Connect Biopharma (CNTB) - The Clock Is Set, The Cushion Is Gone 🔒 Paid
- 2026-06-08 Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Connect Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-08 Watch Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products Differentiated mechanism and real acute-exacerbation white space, but the entire equity hinges on one funded-but-binary mid-2026 Seabreeze readout in a novel endpoint, against subgroup-heavy supporting data and a China-structure/Phase-3-dilution overhang.
- 2026-08-13 Speculative buy speculative UPDATE: Connect Biopharma (CNTB) - The Clock Is Set, The Cushion Is Gone Readout now has a firm month (September), both trials finished enrollment at plan with no futility stop, and Simcere milestone cash is flowing — asymmetry intact on a validated target with a differentiated mechanism, but sized only as a starter given the thinned cash cushion.
- 2026-09-16 Watch UPDATE: Connect Biopharma (CNTB) - The Trial Failed. The Drug Might Not Have. Asthma primary endpoint missed (p=0.153, 8 total events) while the Week-1 FEV₁ secondary hit, leaving a split result that forces a dilutive raise from a broken tape without the clean re-rating needed to finance Phase 3.
- 2026-09-30 Watch UPDATE: Connect Biopharma (CNTB) - The Mirror Image COPD hit the clinical-outcome primary (81% fewer treatment failures, p=0.0122) but missed Day-7 FEV₁, giving two trials pointing the same direction on treatment failure but never both endpoints in the same disease; the balance sheet dilution event remains the binding constraint and the upgrade trigger.
- 2026-11-17 Avoid UPDATE: Connect Biopharma (CNTB) - The Going-Concern Flag Going-concern warning, Nasdaq deficiency notice, and ATM drip sales instead of a priced institutional raise mean the dilution path has gone the bad way — owning the stock now means financing the company on its worst terms despite two trials pointing the same direction on treatment failure.
- Long call · opened Aug 13, 2026 at $2.54 · closed Sep 16, 2026 (downgraded to WATCH from long) at $1.24 · -51.2% vs XBI -1.7%
- Avoid call · opened Nov 17, 2026 at $0.579 · 0.0% vs XBI 0.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 4 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We plan to meet with the FDA in December 2026 to gain alignment on a potential Phase 3 registrational program for asthma and in the first quarter of 2027 for COPD.”
matched to Rademikibart · regulatory submission
-
-
-
“The Company plans to meet with the FDA to gain alignment on potential Phase 3 registrational programs in asthma in December 2026 and for COPD in first quarter of 2027.”
matched to Rademikibart · regulatory submission
-
-
-
“Topline data from both studies are expected in September 2026, which should help determine a potential Phase 3 endpoint and sample size requirements.”
matched to Rademikibart · regulatory submission
-
-
-
“Topline data from both studies are expected in September 2026, which should help determine a potential Phase 3 endpoint and sample size requirements. ◦ Following topline results, the Company plans to meet with the FDA to gain alignment on a Phase 3 program.”
matched to Rademikibart · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseConnect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q landed after today's close with a formal going-concern disclosure, a Nasdaq bid-price deficiency notice received November 12, and a footnote revealing Connect already sold 1.5M shares via ATM in October for just $1.8M in net proceeds (~$1.20/share) — the dilution trap I warned about has sprung.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Sep 30, 2026ReleaseConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation→ BD updateSummary on the 8-K
- Sep 30, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateSeabreeze STAT COPD hit — rademikibart cut treatment failure 81% (p=0.0122) and eliminated all hospital/ED returns — delivering the clean primary endpoint the asthma trial couldn't generate two weeks ago, while the key FEV₁ secondary missed and the financing clock keeps ticking.BD extracted 1 program update from this document → CNTB pipeline
- Sep 15, 2026ReleaseConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Ast→ BD updateSummary on the 8-K
- Sep 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe Seabreeze STAT Asthma coin has landed — and it landed on its edge. Rademikibart's Day 7 FEV₁ signal hit (Δ130 mL, p=0.023), but the primary treatment-failure endpoint missed statistical significance (p=0.153), and the stock has cratered ~50% on data that the company is calling "positive."BD extracted 1 program update from this document → CNTB pipeline
- Sep 3, 2026ReleaseConnect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 12, 2026ReleaseConnect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1
- Aug 12, 202610-QQuarterly reportBD extracted 1 program update from this document → CNTB pipeline
- May 15, 2026F-3Shelf registration (foreign)
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 23, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 1, 2026SCHEDULE 13D/A13D amendment
- Mar 31, 20268-KCurrent report: results of operations · EX-99.1
- Mar 31, 202610-KAnnual report
- Mar 30, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 3, 2026SCHEDULE 13G/A13G amendment
- Oct 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jun 1, 2026EFFECTRegistration effective
- May 28, 2026CORRESPCORRESP
- May 22, 2026UPLOADUPLOAD
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 14, 2026SCHEDULE 13GPassive >5% holder (13G)